Condition
Endometrioid Carcinoma
Total Trials
5
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Recruiting2
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06549855Not ApplicableRecruiting
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
NCT02598219Phase 3Active Not Recruiting
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
NCT03875820Phase 1Active Not Recruiting
Phase I Trial of Defactinib and VS-6766.
NCT05080556Phase 2Recruiting
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT01732432WithdrawnPrimary
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Showing all 5 trials